Thrailkill KM - Search Results

1

Investigational agents for the treatment of growth hormone-insensitivity syndrome.

Kemp SF, Thrailkill KM. Kemp SF, et al. Among authors: thrailkill km. Expert Opin Investig Drugs. 2006 Apr;15(4):409-15. doi: 10.1517/13543784.15.4.409. Expert Opin Investig Drugs. 2006. PMID: 16548790 Review.

2

Efficacy and safety of mecasermin rinfabate.

Kemp SF, Fowlkes JL, Thrailkill KM. Kemp SF, et al. Among authors: thrailkill km. Expert Opin Biol Ther. 2006 May;6(5):533-8. doi: 10.1517/14712598.6.5.533. Expert Opin Biol Ther. 2006. PMID: 16610982

3

SomatoKine: is there a use in treating growth disorders?

Kemp SF, Thrailkill KM. Kemp SF, et al. Among authors: thrailkill km. Curr Opin Investig Drugs. 2005 Apr;6(4):373-7. Curr Opin Investig Drugs. 2005. PMID: 15898344 Review.

4

Stimulant medication use and response to growth hormone therapy: an NCGS database analysis.

Frindik JP, Morales A, Fowlkes J, Kemp S, Thrailkill K, Lippe B, Dana K. Frindik JP, et al. Horm Res. 2009;72(3):160-6. doi: 10.1159/000232491. Epub 2009 Sep 1. Horm Res. 2009. PMID: 19729947 Clinical Trial.

5

Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues.

Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Thrailkill KM, et al. Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E735-45. doi: 10.1152/ajpendo.00159.2005. Am J Physiol Endocrinol Metab. 2005. PMID: 16215165 Free PMC article. Review.

6

Insulin pump therapy started at the time of diagnosis: effects on glycemic control and pancreatic β-cell function in type 1 diabetes.

Thrailkill KM, Moreau CS, Swearingen C, Rettiganti M, Edwards K, Morales AE, Kemp SF, Frindik JP, Fowlkes JL. Thrailkill KM, et al. Diabetes Technol Ther. 2011 Oct;13(10):1023-30. doi: 10.1089/dia.2011.0085. Epub 2011 Jun 30. Diabetes Technol Ther. 2011. PMID: 21718094 Clinical Trial.

7

Matrix metalloproteinase-2 dysregulation in type 1 diabetes.

Thrailkill KM, Bunn RC, Moreau CS, Cockrell GE, Simpson PM, Coleman HN, Frindik JP, Kemp SF, Fowlkes JL. Thrailkill KM, et al. Diabetes Care. 2007 Sep;30(9):2321-6. doi: 10.2337/dc07-0162. Epub 2007 Jun 11. Diabetes Care. 2007. PMID: 17563344 Free PMC article. Clinical Trial.

8

GAD-alum immunotherapy in Type 1 diabetes mellitus.

Morales AE, Thrailkill KM. Morales AE, et al. Among authors: thrailkill km. Immunotherapy. 2011 Mar;3(3):323-32. doi: 10.2217/imt.11.9. Immunotherapy. 2011. PMID: 21395375 Review.

9

Osteo-promoting effects of insulin-like growth factor I (IGF-I) in a mouse model of type 1 diabetes.

Fowlkes JL, Nyman JS, Bunn RC, Jo C, Wahl EC, Liu L, Cockrell GE, Morris LM, Lumpkin CK Jr, Thrailkill KM. Fowlkes JL, et al. Among authors: thrailkill km. Bone. 2013 Nov;57(1):36-40. doi: 10.1016/j.bone.2013.07.017. Epub 2013 Jul 23. Bone. 2013. PMID: 23886838 Free PMC article.

10

Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I/IGF-binding protein-3 complexes.

Fowlkes JL, Serra DM, Bunn RC, Thrailkill KM, Enghild JJ, Nagase H. Fowlkes JL, et al. Among authors: thrailkill km. Endocrinology. 2004 Feb;145(2):620-6. doi: 10.1210/en.2003-0636. Epub 2003 Nov 6. Endocrinology. 2004. PMID: 14605000

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page